The U.S. Centers for Disease Control and Prevention panel of vaccine experts will vote on shots for respiratory syncytial ...

A virus that once filled pediatric hospital beds and terrified new parents is finally being pushed back—before babies are ...

Newer formulations are even more effective at preventing illnesses that commonly afflict seniors — perhaps even dementia.

In advance of this week's CDC vaccine advisory meeting, HHS Secretary Robert F. Kennedy Jr. restacked the committee, claiming ...

A senior scientist at the US CDC has resigned, warning that changes in leadership may weaken the country’s vaccine program.

Kennedy Jr. in the country's top health position, use of a long-approved vaccine against measles, mumps, rubella, and ...

A newly posted agenda for next week’s meeting of the just-appointed group of outside vaccine advisers to the US Centers for ...

Dr. Fiona Havers, who studied medicine at the University of Washington, says the wholesale dismissal of the CDC's scientific ...

RSV is the most common cause of hospitalization in babies, but Sanofi is one of a few companies producing a shot that can ...

The FDA has approved clesrovimab, marketed as Enflonsia, for the prevention of RSV lower respiratory tract disease in ...

In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from ...

vaccine effectiveness from October 2023 to March 2024 against RSV-associated hospitalization reached 75% (95% CI 50-87), according to researchers led by Diya Surie, MD, of the CDC in Atlanta.